120
Participants
Start Date
September 30, 2014
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2024
Guanfacine
"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
Placebo
"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
MGH Center for Translational Pain Research, Boston
National Institutes of Health (NIH)
NIH
National Institute on Drug Abuse (NIDA)
NIH
Massachusetts General Hospital
OTHER